UNSPSC 51433909: Omapatrilat

This classification denotes an ace inhibitor with the molecular formula C19H24N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36NLI90E7T, chemically known as 7h-pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-(((2s)-2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo-, (4s,7s,10as)- but generally known as omapatrilat, which bears US NIH Compound Identifier 126046. European Medicines Agency schedules Omapatrilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12450MIG.

UNSPSC 51433909 Omapatrilat, a Commodity code, covers pharmaceutical products supplied to state and local emergency response, public health, and multistate cooperative purchasing programs. State and local governments buy specific branded and generic medications—including vasodilators, inotropes, antiarrhythmics, and calcium channel blockers—through competitive sealed bids, cooperative purchasing RFPs, and exploratory RFIs that establish ongoing supply contracts with manufacturers, wholesalers, and authorized distribution channels. Issuing bodies include municipal fire and rescue departments (such as Tampa Fire Rescue), state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across state and local members. Procurement authority is distributed across city purchasing departments, state procurement offices, and cooperative alliance administrators; the City of Tampa and the Minnesota Multistate Cooperative Purchasing Alliance appear as active recent buyers.

Recent activity spans Florida and Minnesota, with exploratory procurement also underway in Texas. The City of Tampa's Purchasing Department solicited sealed bids (26P00188) for advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem, with a due date of April 8, 2026, and an estimated contract value of $40,000.00, offering a 5 percent SLBE bid discount not to exceed $10,000. The Minnesota Department of Administration's Office of State Procurement, acting through MMCAP, issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to partner with three authorized wholesalers and meet cGMP and DSCSA compliance. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in early April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment models outside traditional PBM and GPO channels, signaling future formal procurement but no award or budget at the information-gathering stage.